Advertisements for personalized GLP-1 weight-loss drugs are now as pervasive as they are dangerous.

There’s already a robust national debate about direct-to-consumer pharmaceutical advertising. But regardless of where you fall in that debate, everyone can agree: Ads that fail to follow even basic disclosure rules — and target vulnerable people with misleading health claims — deserve serious scrutiny and enforcement.